The SAPIEN 3 and EVOLUT LR trials offer a good platform for assessing the long-term durability of TAVI. However, potential differences between these trials warrant careful consideration in comparative analyses. Head-to-head trials powered for clinical endpoints remain critical.

In the OPERA-TAVI registry, matched patients undergoing TAVI using Evolut PRO/PRO+ and Sapien 3 ULTRA devices exhibited comparable rates of the composite endpoint of all-cause mortality, rehospitalisation for heart failure, or disabling stroke at 1 year. eurointervention.pcronline.com/article/one-ye…

In this state-of-the-art review from the #PCRLV 2023 issue, the Authors propose an overview on transcatheter mitral valve replacement (TMVR) for the treatment of native mitral valve disease, from indication to results, with a glimpse into the future.
eurointervention.pcronline.com/article/transc…

Alternative administration modes for ticagrelor (i.e., crushed, chewed, or orodispersible tablets) are an alternative to overcome the limitations associated with its delayed onset of action in patients who are unable to swallow or with impaired absorption. ddec1-0-en-ctp.trendmicro.com/wis/clicktime/…

You will have experienced that bad feeling once in your life that at any moment someone could point out a typo in a paper whose draft you have proofread eighteen times. Sorry if I do it too, but knowing that these things also happen on NEJM is a morale-boosting thing.

Even pineapple juice can cause less bleeding than rivaroxaban, but then we need to see if it protects as much from ischemic stroke. The results of the AZALEA-TIMI 71 study encourage going to phase 3 with the 150 mg dose. This is currently being studied in the LILAC-TIMI 76 trial.

Since today there was not enough confusion in the galaxy of coronary revascularization, here is the ISCHEMIA analysis that we were all (not) waiting for, with its cumulative incidence curves at serious risk of misunderstandings. jacc.org/doi/10.1016/j.…

My post-coronary angiography patient talk revisited after ORBITA and ORBITA-2: 'Dear patient with chest pain and no pills, if I fix this artery you won't live one day longer, but you may have less angina, or you can take one or more pills and achieve more or less the same'.

ORBITA-2, the revenge. In a randomized, placebo-controlled trial of 301 patients with stable angina who stopped all antianginal medications and had evidence of ischemia, the mean angina symptoms score at 12 weeks was lower with PCI than placebo. nejm.org/doi/full/10.10…

In SELECT, the GLP-1-RA semaglutide, at a dose of 2.4 mg, reduced by 20% the risk of ischemic events at a mean of ~40 months compared with placebo (NNT=66) in 17604 patients with cardiovascular disease and overweight or obesity but no history of diabetes. nejm.org/doi/full/10.10…

In this prospective TAVI registry of 2,090 patients across the hemodynamic spectrum of severe aortic stenosis, the cardiac damage staging classification stratified the risk of death irrespective of aortic stenosis subtypes (e.g., high or low gradient). eurointervention.pcronline.com/article/progno…

In this study, we investigated the phenomenon of simultaneous publication of cardiovascular trials and found some predictors. Simultaneous publications were associated with higher citation and mention metrics compared with nonsimultaneous publications.
sciencedirect.com/science/articl…

The goal of guided DAPT is to intensify or decrease the antiplatelet potency based on risk. We wrote this article to present an up-to-date overview of the latest research findings on DAPT modulation guided by either platelet function or genetic testing. ahajournals.org/doi/10.1161/CI…

Clinical valve thrombosis was 2.5% with TAVI the in PARTNER 3 trial at 5 years. Patients with clinical valve thrombosis should start anticoagulation for at least 3 months. In case of no resolution and worsening symptoms, aortic reintervention should be considered. #TCT2023

In T-PASS, aspirin discontinuation after a median of 16 days, followed by ticagrelor monotherapy, was superior for NACE compared with 12-mo DAPT in 2850 patients with ACS, with less bleeding. But KM curves opened late, which is a bit puzzling. #TCT2023 ahajournals.org/doi/10.1161/CI…

AGENT IDE presented at #TCT2023 . In patients with in-stent restenosis, the Agent drug-coated balloon reduced the risk of TLF at 1 year versus POBA, with a NNT of 9. A somewhat inexplicable applause broke out in the room given the obviousness of the result (at least in Europe).

And here again are the resorbable scaffolds, which restart their journey below the knee. In LIFE-BTK, compared with PTA, the Esprit BTK scaffold reduced a composite of limb salvage and primary patency at 1 year, with a number needed to treat of 4. #TCT2023
nejm.org/doi/full/10.10…

In the AVENGER registry, valve-in-valve TAVI using either the ACURATE neo/neo2 or EVOLUT R/PRO/PRO+ transcatheter heart valves showed similar procedural outcomes, but differences between the two devices emerged depending on the inner diameter. #TCT2023 eurointervention.pcronline.com/article/compar…

Five year results of PARTNER 3 trial now published in the NEJM. Conclusions are based on the primary composite outcomes, but two aspects will be a reason for discussion, I guess: crossing of death curves, and the higher rate of valve thrombosis with TAVI.
nejm.org/doi/full/10.10…

In the ROTACUT trial, lesion preparation with rotational atherectomy followed by cutting balloon angioplasty did not result in more optimal stent expansion compared with rotational atherectomy followed by non-compliant balloon post-dilatation. #TCT2023 eurointervention.pcronline.com/article/rotati…